A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Exactech Shares Industry’s First Shoulder Replacement Surgery “Smart Score” Metric Based on Machine Learning

Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today the first orthopaedic clinical outcomes measure based on machine learning.

The Shoulder Arthroplasty Smart (SAS, or “Smart”) Score quantifies clinical outcomes for shoulder arthroplasty patients so surgeons can determine how well patients are doing before and after surgery. The score is available to any surgeon or researcher through the website.

Unlike existing scores available in the industry, the Smart Score offers surgeons a more efficient means of measuring patient outcomes by requiring only half the inputs of other scores. With just six patient-specific inputs, determined through machine learning research to be the most significant assessments of post-operative outcomes, the Smart Score (ranging from 0-100) is determined for each patient.

The score is based on three objective active range of motion measures and three subjective measures of the patient’s pain and function. The Smart Score will be used as part of Exactech’s new Predict+™ clinical decision support tool that uses machine learning to provide predictions of individual patient outcomes after shoulder replacement surgery.

A paper recently published in JSES Seminars in Arthroplasty concluded that machine learning can help create more efficient and effective clinical outcome measures. Another paper published this week in the Journal of Shoulder and Elbow Surgery compared the new Smart Score to five other assessment tools currently available and found that it was more efficient, with fewer inputs, and showed equivalent or better validity, responsiveness and clinical interpretability.

“Historically, there has not been a single gold standard tool to quantify outcomes before and after shoulder replacement surgery,” said orthopaedic surgeon Joseph Zuckerman, MD, of NYU Langone Orthopedic Hospital, and an Equinoxe® shoulder replacement system design team surgeon. “Because of that, shoulder surgeons have used many different generic shoulder outcome scores to quantify pain relief or functional improvement after shoulder arthroplasty. Our clinical research detailed in this publication proposed a new shoulder arthroplasty-specific clinical outcome score, the Shoulder Arthroplasty Smart Score, that more accurately and efficiently quantifies outcomes, without the bias, ceiling effects or response range issues of the other scores.”

Exactech Vice President of Extremities Chris Roche added, “Three of the most common tools to quantify clinical outcomes in the shoulder are the ASES, Constant and UCLA scores. These tools were developed 30 years ago and have changed little since that time despite significant advances in treatment and data science. New machine learning-based analyses provide an opportunity to evaluate the predictive validity of these historical tools.

He concluded, “In fact, our research identified the preoperative input questions that are predictive of clinical outcomes, and those that aren’t predictive. We also found that the majority of the inputs composing these three historical clinical tools were of low predictive validity, suggesting the need for an altogether new tool like the Smart Score, with preoperative inputs that are more correlated to post-operative outcomes after shoulder surgery.”

SourceExactech
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy